Prognostic value of maximum standard uptake value, metabolic tumor volume, and total lesion glycolysis of 18F-FDG PET/CT in patients with renal carcinoma A protocol for systematic review and meta analysis

被引:7
作者
Xuan, Dongchun [1 ,2 ]
Wen, Weibo [1 ,2 ]
Tian, Shengri [3 ]
Piao, Minhu [3 ]
Xu, Dongyuan [1 ]
Liu, Lan [4 ]
机构
[1] Yanbian Univ, Ctr Morphol Expt, Med Coll, Yanji, Jilin, Peoples R China
[2] Yanbian Univ Hosp, Dept Nucl Med, Yanji, Jilin, Peoples R China
[3] Yanbian Univ Hosp, Dept Urol, Yanji, Jilin, Peoples R China
[4] Yanbian Univ Hosp, Dept Pathol, Yanji, Jilin, Peoples R China
基金
中国国家自然科学基金;
关键词
maximal standard uptake value; meta-analysis; metabolic tumor volume; positron emission tomography; computed tomography; renal carcinoma; total lesional glycolysis; POSITRON-EMISSION-TOMOGRAPHY; INTERFERON-ALPHA; FDG-PET/CT; CERVICAL-CANCER; PARAMETERS; SURVIVAL; SUNITINIB; MODEL;
D O I
10.1097/MD.0000000000019988
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose: We present a comprehensive systematic review of the documented literature on parameters derived from(18)F-fluorodeoxyglucose positron emission tomography (F-18-FDG PET) and meta-analysis of the prognostic value of maximal standard uptake value (SUVmax), metabolic tumor volume (MTV) and total lesional glycolysis (TLG) in patients with renal carcinoma (RCC). Patients and methods: Relevant articles in English from PubMed, EMBASE, and the Cochrane Library were retrieved. Pooled hazard ratio (HR) values were used to assess the prognostic value of SUVmax, MTV, and TLG. Results: A total of 10 primary studies involving 780 patients with RCC were included. The combined HRs for event-free survival were 1.32 (95% CI 1.10-1.58) for SUVmax, 2.40 (95% CI 1.20-4.79) for MTV, and 3.31 (95% CI 1.68-6.50) for TLG. Pooled HRs for overall survival were 1.264 (95% CI 1.124-1.421) for SUVmax, 3.52 (95% CI 1.451-8.536) for MTV, and 6.33 (95% CI 1.32-30.30) for TLG. Subgroup analysis revealed SUVmax as an independent risk factor for patients with recurrence or metastasis. Conclusion: The present meta-analysis confirmed that despite the clinical heterogeneity of RCC and adoption of various methods between studies, high SUVmax is a significant prognostic factor, especially in patients with recurrence or metastasis. MTV and TLG were associated with prediction of higher risk of adverse events or death in patients with RCC.
引用
收藏
页数:10
相关论文
共 44 条
[1]  
Afifi AHA, 2017, EGYPT J RADIOL NUC M, V48, P677, DOI 10.1016/j.ejrnm.2017.03.008
[2]  
Bachor R, 1996, UROLOGE A, V35, P146
[3]   FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0 [J].
Boellaard, Ronald ;
Delgado-Bolton, Roberto ;
Oyen, Wim J. G. ;
Giammarile, Francesco ;
Tatsch, Klaus ;
Eschner, Wolfgang ;
Verzijlbergen, Fred J. ;
Barrington, Sally F. ;
Pike, Lucy C. ;
Weber, Wolfgang A. ;
Stroobants, Sigrid ;
Delbeke, Dominique ;
Donohoe, Kevin J. ;
Holbrook, Scott ;
Graham, Michael M. ;
Testanera, Giorgio ;
Hoekstra, Otto S. ;
Zijlstra, Josee ;
Visser, Eric ;
Hoekstra, Corneline J. ;
Pruim, Jan ;
Willemsen, Antoon ;
Arends, Bertjan ;
Kotzerke, Joerg ;
Bockisch, Andreas ;
Beyer, Thomas ;
Chiti, Arturo ;
Krause, Bernd J. .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 42 (02) :328-354
[4]   Epidemiology and risk factors for kidney cancer [J].
Chow, Wong-Ho ;
Dong, Linda M. ;
Devesa, Susan S. .
NATURE REVIEWS UROLOGY, 2010, 7 (05) :245-257
[5]   A randomized-controlled trial of prophylactic hydrocortisone supplementation for the prevention of hypotension in extremely low birth weight infants [J].
Efird M.M. ;
Heerens A.T. ;
Gordon P.V. ;
Bose C.L. ;
Young D.A. .
Journal of Perinatology, 2005, 25 (2) :119-124
[6]  
Escudier B, 2007, SORAFENIB ADV CLEAR, V25, P443
[7]   Volumetric FDG-PET predicts overall and progression- free survival after 14 days of targeted therapy in metastatic renal cell carcinoma [J].
Farnebo, Jacob ;
Gryback, Per ;
Harmenberg, Ulrika ;
Laurell, Anna ;
Wersall, Peter ;
Blomqvist, Lennart K. ;
Ullen, Anders ;
Sandstrom, Per .
BMC CANCER, 2014, 14
[8]   Japanese guideline for the oncology FDG-PET/CT data acquisition protocol: synopsis of Version 2.0 [J].
Fukukita, Hiroyoshi ;
Suzuki, Kazufumi ;
Matsumoto, Keiichi ;
Terauchi, Takashi ;
Daisaki, Hiromitsu ;
Ikari, Yasuhiko ;
Shimada, Naoki ;
Senda, Michio .
ANNALS OF NUCLEAR MEDICINE, 2014, 28 (07) :693-705
[9]   Positron Emission Tomography (PET) in Oncology [J].
Gallamini, Andrea ;
Zwarthoed, Colette ;
Borra, Anna .
CANCERS, 2014, 6 (04) :1821-1889
[10]   Summary of the UPICT Protocol for 18F-FDG PET/CT Imaging in Oncology Clinical Trials [J].
Graham, Michael M. ;
Wahl, Richard L. ;
Hoffman, John M. ;
Yap, Jeffrey T. ;
Sunderland, John J. ;
Boellaard, Ronald ;
Perlman, Eric S. ;
Kinahan, Paul E. ;
Christian, Paul E. ;
Hoekstra, Otto S. ;
Dorfman, Gary S. .
JOURNAL OF NUCLEAR MEDICINE, 2015, 56 (06) :955-961